Studies have shown that PD 173074 significantly reduces the phosphorylation levels of the MAPK pathway in non-small cell lung cancer (NSCLC) with FGFR1 amplification, subsequently reducing ERK phosphorylation, a member of the MAPK family, affecting tumor cell proliferation [73]. This evidence concerns the gene FGFR1 and neoplasm.